Selden Stephens, MD
Urology · Mobile, ALNPI 1114020377
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,872 of the $4,462 with a category attached, or 86.8%. It is spread thinly across 35 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations.
Across 208 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$710
- Astellas Pharma US Inc$523
- Cornerstone Urology Network, LLC$500
- Endo Pharmaceuticals Inc.$366
- Sumitomo Pharma America, Inc.$279
- Dendreon Pharmaceuticals LLC$256
- plus $2K from 29 others
Across 1 payment — averaging $7000.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Cornerstone Urology Network, LLC$7K
What the payments were for
- Consulting fees$50011%
- Food & beverage$3,87287%
- Education$902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 46 | $710 |
| Astellas Pharma US Inc | 31 | $523 |
| Cornerstone Urology Network, LLC | 1 | $500 |
| Endo Pharmaceuticals Inc. | 19 | $366 |
| Sumitomo Pharma America, Inc. | 16 | $279 |
| Dendreon Pharmaceuticals LLC | 7 | $256 |
| Olympus America Inc. | 2 | $196 |
| Antares Pharma, Inc. | 11 | $182 |
| Endo USA, Inc. | 5 | $122 |
| Pfizer | 6 | $108 |
| Coloplast | 3 | $103 |
| Tolmar Pharmaceuticals, Inc. | 6 | $100 |
| Urogen Pharma, Inc. | 6 | $95 |
| Myovant Sciences Inc. | 6 | $90 |
| Blue Earth Diagnostics | 4 | $88 |
| AbbVie | 6 | $88 |
| Procept Biorobotics Corporation | 2 | $79 |
| Urovant Sciences Inc | 4 | $75 |
| Myriad Genetic Laboratories, Inc. | 4 | $68 |
| Merck | 3 | $68 |
| Novartis | 3 | $55 |
| Baxter Healthcare | 2 | $36 |
| Verity Pharmaceuticals Inc. | 2 | $31 |
| Axonics, Inc. | 2 | $28 |
| Boston Scientific | 1 | $27 |
| Amgen | 1 | $26 |
| Progenics Pharmaceuticals, Inc. | 1 | $26 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Rochester Medical Corporation | 1 | $18 |
| Convatec Inc. | 1 | $17 |
| Accord Healthcare, Inc. | 1 | $16 |
| Neotract Inc. | 1 | $16 |
| 180 Medical, Inc. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Olympus Laser Devices$125
- PROVENGE$125
How this compares
$4,462 in reported general payments places this provider in the 55th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 230 | $594,874 |
| ErleadaApalutamide | 22 | $322,366 |
| GemtesaVibegron | 174 | $113,340 |
| MyrbetriqMirabegron | 161 | $90,246 |
| Testosterone Cypionate | 285 | $15,558 |
| Tamsulosin Hcl | 1,030 | $14,111 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 25 | $4,909 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 176 | $3,891 |
| Testosterone | 43 | $3,795 |
| Finasteride | 335 | $3,480 |
| Cefdinir | 219 | $3,103 |
| Bethanechol Chloride | 29 | $3,022 |
| NitrofurantoinNitrofurantoin Macrocrystal | 92 | $2,889 |
| Oxybutynin Chloride ErOxybutynin Chloride | 163 | $2,847 |
| Methenamine Hippurate | 35 | $2,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $279 | $708,215404 claims |
| Johnson & JohnsonErleada | $710 | $322,36622 claims |
| Astellas Pharma US IncMyrbetriq | $523 | $90,246161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 179 urology providers in Alabama.
Other urology in Mobile
- Lorie FleckMobile$26K
- Zachary ReardonMobile$19K
- Ted KleinMobile$18K
- Austin YoungerMobile$18K
- William BlaylockMobile$13K
- Guy OswaltMobile$9K
- Kristie Blanchard-BurchMobile$8K
- Paul ScottMobile$8K
- William SandersonMobile$7K
- Robert HelmMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.